First Time Loading...

Pacira Biosciences Inc
NASDAQ:PCRX

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
NASDAQ:PCRX
Watchlist
Price: 25.5 USD -1.54% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. [ Read More ]

The intrinsic value of one PCRX stock under the Base Case scenario is 64.11 USD. Compared to the current market price of 25.5 USD, Pacira Biosciences Inc is Undervalued by 60%.

Key Points:
PCRX Intrinsic Value
Base Case
64.11 USD
Undervaluation 60%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Pacira Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling PCRX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Pacira Biosciences Inc

Provide an overview of the primary business activities
of Pacira Biosciences Inc.

What unique competitive advantages
does Pacira Biosciences Inc hold over its rivals?

What risks and challenges
does Pacira Biosciences Inc face in the near future?

Has there been any significant insider trading activity
in Pacira Biosciences Inc recently?

Summarize the latest earnings call
of Pacira Biosciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Pacira Biosciences Inc.

Provide P/S
for Pacira Biosciences Inc.

Provide P/E
for Pacira Biosciences Inc.

Provide P/OCF
for Pacira Biosciences Inc.

Provide P/FCFE
for Pacira Biosciences Inc.

Provide P/B
for Pacira Biosciences Inc.

Provide EV/S
for Pacira Biosciences Inc.

Provide EV/GP
for Pacira Biosciences Inc.

Provide EV/EBITDA
for Pacira Biosciences Inc.

Provide EV/EBIT
for Pacira Biosciences Inc.

Provide EV/OCF
for Pacira Biosciences Inc.

Provide EV/FCFF
for Pacira Biosciences Inc.

Provide EV/IC
for Pacira Biosciences Inc.

Show me price targets
for Pacira Biosciences Inc made by professional analysts.

What are the Revenue projections
for Pacira Biosciences Inc?

How accurate were the past Revenue estimates
for Pacira Biosciences Inc?

What are the Net Income projections
for Pacira Biosciences Inc?

How accurate were the past Net Income estimates
for Pacira Biosciences Inc?

What are the EPS projections
for Pacira Biosciences Inc?

How accurate were the past EPS estimates
for Pacira Biosciences Inc?

What are the EBIT projections
for Pacira Biosciences Inc?

How accurate were the past EBIT estimates
for Pacira Biosciences Inc?

Compare the revenue forecasts
for Pacira Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pacira Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pacira Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pacira Biosciences Inc compared to its peers.

Compare the P/E ratios
of Pacira Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Pacira Biosciences Inc with its peers.

Analyze the financial leverage
of Pacira Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Pacira Biosciences Inc.

Provide ROE
for Pacira Biosciences Inc.

Provide ROA
for Pacira Biosciences Inc.

Provide ROIC
for Pacira Biosciences Inc.

Provide ROCE
for Pacira Biosciences Inc.

Provide Gross Margin
for Pacira Biosciences Inc.

Provide Operating Margin
for Pacira Biosciences Inc.

Provide Net Margin
for Pacira Biosciences Inc.

Provide FCF Margin
for Pacira Biosciences Inc.

Show all solvency ratios
for Pacira Biosciences Inc.

Provide D/E Ratio
for Pacira Biosciences Inc.

Provide D/A Ratio
for Pacira Biosciences Inc.

Provide Interest Coverage Ratio
for Pacira Biosciences Inc.

Provide Altman Z-Score Ratio
for Pacira Biosciences Inc.

Provide Quick Ratio
for Pacira Biosciences Inc.

Provide Current Ratio
for Pacira Biosciences Inc.

Provide Cash Ratio
for Pacira Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Pacira Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Pacira Biosciences Inc?

What is the current Free Cash Flow
of Pacira Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pacira Biosciences Inc.

Financials

Balance Sheet Decomposition
Pacira Biosciences Inc

Current Assets 510m
Cash & Short-Term Investments 278.6m
Receivables 105.6m
Other Current Assets 125.9m
Non-Current Assets 1.1B
Long-Term Investments 38.5m
PP&E 234.9m
Intangibles 646.5m
Other Non-Current Assets 144.5m
Current Liabilities 97.4m
Accounts Payable 15.7m
Accrued Liabilities 73m
Other Current Liabilities 8.6m
Non-Current Liabilities 606.9m
Long-Term Debt 513.8m
Other Non-Current Liabilities 93.1m
Efficiency

Earnings Waterfall
Pacira Biosciences Inc

Revenue
675m USD
Cost of Revenue
-184.7m USD
Gross Profit
490.3m USD
Operating Expenses
-403m USD
Operating Income
87.3m USD
Other Expenses
-45.4m USD
Net Income
42m USD

Free Cash Flow Analysis
Pacira Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

PCRX Profitability Score
Profitability Due Diligence

Pacira Biosciences Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROIC
Positive 3-Years Revenue Growth
55/100
Profitability
Score

Pacira Biosciences Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

PCRX Solvency Score
Solvency Due Diligence

Pacira Biosciences Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Positive Net Debt
51/100
Solvency
Score

Pacira Biosciences Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PCRX Price Targets Summary
Pacira Biosciences Inc

Wall Street analysts forecast PCRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PCRX is 46.24 USD with a low forecast of 36.36 USD and a high forecast of 59.85 USD.

Lowest
Price Target
36.36 USD
43% Upside
Average
Price Target
46.24 USD
81% Upside
Highest
Price Target
59.85 USD
135% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

PCRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

PCRX Price
Pacira Biosciences Inc

1M 1M
-11%
6M 6M
-7%
1Y 1Y
-42%
3Y 3Y
-61%
5Y 5Y
-36%
10Y 10Y
-61%
Annual Price Range
25.5
52w Low
25.5
52w High
46.6
Price Metrics
Average Annual Return 2.64%
Standard Deviation of Annual Returns 28.35%
Max Drawdown -69%
Shares Statistics
Market Capitalization 1.2B USD
Shares Outstanding 46 500 800
Percentage of Shares Shorted 11.19%

PCRX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Pacira Biosciences Inc Logo
Pacira Biosciences Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

1.2B USD

Dividend Yield

0%

Description

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Contact

FLORIDA
Tampa
5401 West Kennedy Boulevard, Suite 890
+18135536680.0
http://www.pacira.com/

IPO

2011-02-03

Employees

697

Officers

Chief Financial Officer
Mr. Charles A. Reinhart III, CPA, M.B.A.
Chief Operating Officer
Mr. Daryl Gaugler
Chief Administrative Officer & Secretary
Ms. Kristen Williams J.D.
Chief Legal & Compliance Officer
Mr. Anthony Molloy III, Esq.
Advisor
Mr. David M. Stack
CEO & Director
Mr. Frank D. Lee
Show More
Principal Accounting Officer & Senior VP of Finance
Ms. Lauren Bullaro Riker
Head of Investor Relations
Susan Mesco
Vice President of Human Resources
Mr. Richard Kahr
Chief Customer Officer
Mr. Dennis McLoughlin
Show Less

See Also

Discover More
What is the Intrinsic Value of one PCRX stock?

The intrinsic value of one PCRX stock under the Base Case scenario is 64.11 USD.

Is PCRX stock undervalued or overvalued?

Compared to the current market price of 25.5 USD, Pacira Biosciences Inc is Undervalued by 60%.